Enlivex Therapeutics .(ENLV) - 2018 Q4 - Annual Report

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission file number: 001-36578 Enlivex Therapeutics Ltd. (Exact name of Registrant as specified in its charter) State of Israel (Jurisdiction of incorporation or organization) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) Mr. Shmuel Hess Tel: +972.2.6708072 ...